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Context: Pseudohypoparathyroidism type Ia (PHP1A) is caused by inactivating
mutations involving GNAS exons 1–13, encoding the alpha-subunit of the stimulatory
G protein (Gsα). Particularly PHP1A, but also other disorders involving the Gsα-cAMP-
signaling pathway, have been associated with early-onset obesity. Thus, patients with
mutations in the genes encoding PDE4D and PRKAR1A can also be obese. Furthermore,
epigenetic GNAS changes, as in pseudohypoparathyroidism type Ib (PHP1B), can lead
to excessive weight.
Objective: Search for genetic variants in GNAS, PDE4D, and PRKAR1A and for
methylation alterations at theGNAS locus in Finnish subjects with isolated severe obesity
before age 10 years.
Methods: Next generation sequencing to identify pathogenic variants in the
coding exons of GNAS, PDE4D, and PRKAR1A; Multiplex Ligation-dependent Probe
Amplification (MLPA) and methylation-sensitive MLPA (MS-MLPA) to search for deletions
in GNAS and STX16, and for epigenetic changes at the four differentially methylated
regions (DMR) within GNAS.
Results: Among the 88 subjects (median age 13.8 years, median body mass index
Z-score +3.9), we identified one rare heterozygous missense variant of uncertain
significance in the XL exon of GNAS in a single patient. We did not identify clearly
pathogenic variants in PDE4D and PRKAR1A, and no GNAS methylation changes were
detected by MS-MLPA.
Loid et al. GNAS Defects Uncommon in Obesity
Conclusions: Our results suggest that codingGNASmutations or methylation changes
at the GNAS DMRs, or coding mutations in PDE4D and PRKAR1A are not common
causes of isolated childhood obesity in Finland.
Keywords: GNAS, G protein-cAMP-signaling, childhood-onset obesity, pseudohypoparathyroidism,
acrodysostosis
INTRODUCTION
Pseudohypoparathyroidism (PHP) and related disorders have
been associated with early-onset obesity (1, 2). These diseases,
which can present with highly variable clinical findings (3),
are caused by a defect in the stimulatory G protein-cAMP-
signaling pathway.
GNAS is a complex imprinted locus on chromosome 20q13.3.
Exons 1–13 encode the alpha-subunit of the stimulatory G
protein (Gsα), a signaling protein mediating the functions of
several hormones that require the second messenger cAMP
down-stream of their cognate receptors (3). GNAS also encodes
several other transcripts with incompletely defined biological
actions, including the mRNAs encoding the neuroendocrine
secretory protein 55 (NESP55) and the extra-large form of Gsα
(XLαs), as well as the A/B and the antisense (AS) transcript.
The Gsα transcript is biallelically expressed in most
but not all tissues; the paternal expression is reduced in
several tissues, e.g., proximal renal tubules, thyroid, gonads,
brown adipose tissue, hypothalamus, and pituitary gland (3).
Clinical and laboratory manifestations of GNAS mutations are
therefore determined by the parental origin of the mutated
allele. Mutations involving exons 1–13 of the maternal
GNAS allele underlie pseudohypoparathyroidism type 1A
(PHP1A) in which patients develop resistance to PTH in the
proximal renal tubules leading to elevated plasma PTH levels,
hypocalcemia and hyperphosphatemia, and often resistance
to multiple other hormones. Patients with PHP1A show
clinical features of Albright’s hereditary osteodystrophy (AHO),
including short stature, brachydactyly, early-onset obesity,
neurodevelopmental defects and subcutaneous ossifications.
In contrast, inactivating mutations located on the paternal
GNAS allele cause pseudopseudohypoparathyroidism (PPHP)
characterized in most patients by several AHO features, but no
hormonal resistance, no obesity, and no intellectual challenges.
Methylation defects at GNAS exon A/B alone, or at several GNAS
DMRs, are observed in pseudohypoparathyroidism type 1B
(PHP1B), characterized by resistance to PTH and frequently
TSH, but infrequently by AHO features (3).
Other genes involved in the Gsα-cAMP-signaling pathway
are PRKAR1A and PDE4D. PRKAR1A encodes the regulatory
subunit of cAMP-dependent protein kinase A (PKA) and PDE4D
encodes the phosphodiesterase 4D. Heterozygous mutations in
PDE4D and PRKAR1A lead to acrodysostosis because cAMP is
either degraded too rapidly or unable to dissociate the regulatory
from the catalytic subunit of PKA. The disorders caused by
mutations in the latter genes present with clinical manifestations
overlapping partly those encountered in PHP (4).
Early-onset obesity can be the first and only evidence for
pseudohypoparathyroidism (2, 5). Several mechanisms can be
responsible for the excessive weight gain. In patients with
PHP1A, reduced energy expenditure caused by the decreased
Gsα-mediated signaling in brown or beige fat cells, as well
as impaired signaling at the melanocortin 4 receptor leading
to hyperphagia and thus increased caloric intake have been
proposed as important mechanisms leading to obesity (6–8).
Furthermore, the resistance to TSH and growth hormone-
releasing-hormone may play a role in the development of obesity
(2). Early-onset and childhood obesity has also been observed in
PHP1B (1, 9). Based on these observations, it has been proposed
that genetic and epigenetic defects at the GNAS locus should be
considered in patients with unexplained childhood obesity (2). In
fact, mutations in the GNAS exons encoding Gsα were recently
identified in a large British cohort of obese patients (10). This
prompted us to look for genetic variants in GNAS, PDE4D, and
PRKAR1A, and for methylation alterations of GNAS locus in
a cohort of Finnish patients who had developed severe obesity
already in early childhood.
MATERIALS AND METHODS
This study included 88 subjects recruited through pediatric
endocrine clinics at Children’s Hospital at Helsinki University
Hospital and Seinäjoki Central Hospital in Finland. The study
was approved by the Research Ethics Committees of the
Hospital District of Helsinki and Uusimaa and the Pirkanmaa
Hospital District. Informed written consent was obtained from
all participants or their guardians (subjects aged <18 years).
The inclusion criterion was severe obesity as defined
according to the Finnish growth standards (11) as height-
adjusted weight >60% before 10 years of age. The patients
had been followed up by a pediatrician and patients who
were diagnosed with a known underlying endocrine or genetic
disorder were excluded from the study. Clinical and growth
data were collected from hospital records. Height, weight and
waist circumference were measured during a study visit. Sex-
and age-specific BMI Z-scores were derived based on the
World Health Organization reference values (www.who.int/
childgrowth/standards).
Genomic DNA was isolated from peripheral blood samples
according to standard procedures. The probes for targeted
exome sequencing were designed using SeqCap EZ Choice
Library and NimbleDesign (Roche NimbleGen, United States).
DNA capture and Next Generation Sequencing were performed
at Oxford Genomics Centre. The reads were aligned to the
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reference genome hg19. The software Platypus version 0.8.1 was
used for variant calling and Ensembl Variant Effector Predictor
(VEP) was used for functional annotation of the variants.
Filtering of variants was performed using VarAFT 2.13 (http://
varaft.eu). Exonic and splice site variants were considered. We
compared the allele frequencies of the identified variants to those
obtained from the Exome Aggregation Consortium (http://
exac.broadinstitute.org), the Genome Aggregation Database
(http://gnomad.broadinstitute.org), 1,000 Genomes Project
(http://www.internationalgenome.org) and the Sequencing
Initiative Suomi project (SISu) (http://sisuproject.fi). The
potential pathogenicity of the sequence variants was evaluated
using different variant prediction databases (Polyphen-2, SIFT,
Combined Annotation Dependent Depletion (CADD) and
MutationTaster2). Sanger sequencing was performed to confirm
findings. Primers were designed using Primer3 software and
PCR was performed using DreamTaqTM DNA Polymerase
(Thermo Fisher Scientific) according to standard protocol and
chromatograms were analyzed with Sequencer v5.0 software.
Primer sequences are available upon request.
Multiplex Ligation-dependent Probe Amplification (MLPA)
to search for GNAS or STX16 deletions and analysis of
the GNAS methylation status, as assessed by methylation
specific multiplex ligation-dependent probe amplification (MS-
MLPA), was performed using kit ME031 GNAS (MRC-Holland,
Amsterdam, The Netherland) following the manufacturer’s
instructions (https://www.mlpa.com/), as described (12). PCR
products were examined using the ABI3730xl Genetic Analyzer
at the DNA Core Facility of the Massachusetts General Hospital
and Peak Scanner 2.0 software (http://peak-scanner-software.
software.informer.com/2.0/). The results obtained for two to five
probes at each of the different DMRs were averaged for each
patient and mean± standard deviation (SD) were subsequently
calculated for each DMR for the entire cohort.
RESULTS
Baseline Characteristics
The median age for the 88 study subjects (54.5% males) was 13.8
years [interquartile range (IQR) 11.1–17.0 years]. The median
BMI Z-score at the time of the study visit was +3.9 (IQR +3.4
to +4.9). The study subjects fulfilled our inclusion criteria of
severe obesity (height-adjusted weight >60%) at the median
age of 5.3 years (IQR 4.1–7.0 years). They had reached height-
adjusted weight >40% (corresponding to obesity according to
Finnish growth standards) at the median age of 4.0 years (IQR
2.0–5.0 years) (Table 1). Of the 68 school-aged subjects for whom
information on learning difficulties was available, 10 (15%) had
learning difficulties and required special education.
Targeted Exome Sequencing
The variants detected in GNAS, PDE4D, and PRKAR1A are
presented in Table 2. We identified one rare heterozygous
missense GNAS variant in exon XL (c.897C>A, p.S299R) in a
female with severe early-onset obesity. This variant is found with
allele frequency 0.00036 in the Finnish population in gnomAD.
Polyphen-2 predicted the variant as possibly damaging, SIFT as
TABLE 1 | Characteristics of study subjects, n = 88.
Male, n (%) 48 (54.5)
Age (yrs) 13.8 (11.1-17.0)
BMI Z-score 3.9 (3.4-4.9)
Age when weight-adjusted height 60% (yrs) 5.3 (4.1-7.0)
Age when weight-adjusted height 40% (yrs) 4.0 (2.0-5.0)
Data presented as median (interquartile range).
tolerated, MutationTaster2 as disease-causing; the CADD score
was high 23. The patient presented with obesity already at 3.5
years of age with weight 24.5 kg and height 105.5 cm (BMI Z-
score +3.8). Presently at the age of 21 years, she has severe
obesity: weigh 121 kg, height 170.5 cm (BMI 42) and waist
circumference 120 cm. The patient did not present with any
hormone resistance or clinical characteristics of AHO apart from
obesity. Both parents were obese, but their DNA samples were
unavailable for genotyping.
Furthermore, five heterozygous variants were identified that
change single amino acids in GNAS exon XL and NESP,
respectively. However, these variants have allele frequencies in
gnomAD comparable to the allele frequencies observed in our
cohort. No variants were identified in the GNAS exons encoding
Gsα. In PDE4D or PRKAR1A, we did not detect any variants that
have previously been shown to be disease-causing.
Multiplex Ligation-Dependent Probe
Amplification
Analysis ofGNASmethylation byMS-MPLA did not identify any
epigenetic alterations at theGNAS locus (Supplemental Table 1);
the DMRs showed no evidence for abnormal methylation at
NESP (53.4 ± 2.5%), AS (53.9 ± 3.1%), XL (53.5 ± 2.9%), and
A/B (52.4± 3.6%).
DISCUSSION
Pseudohypoparathyroidism and acrodysostosis are rare,
heterogeneous disorders caused by different genetic/epigenetic
defects (3). Differential diagnosis between these disorders can
be challenging because of their overlapping clinical and/or
laboratory phenotypes. The clinical features can be difficult
to identify by physical examination and some patients show
only minor clinical abnormalities that furthermore can vary
with age (13). Furthermore, PTH-resistance in PHP1B may
remain undetected until symptomatic hypocalcemia develops
(2). Establishing the correct diagnosis can thus be challenging
but would be of significant importance because of the multiple
endocrine disturbances related to these disorders.
Previous studies have found that obesity is a common clinical
finding in children with pseudohypoparathyroidism type 1A
(2, 5). In a study investigating early features of PHP1A, the major
clinical sign was obesity, present in 70% of children >2 years of
age (5). Furthermore, it has been suggested that GNAS defects in
patients with early-onset obesity may be underestimated, since
Hendricks et al. (10) found several novel variants in GNAS in
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unselected patients with severe obesity, yet no obvious endocrine
defects or short stature. However, many of the patients in the
study by Hendricks et al. with GNAS variants had developmental
delay (10).
We searched for pathogenic variants in GNAS, PDE4D, and
PRKAR1A, and for GNAS methylation changes in 88 Finnish
subjects with isolated severe early-onset obesity. We identified
only one rare heterozygous missense variant in GNAS exon XL
in a patient with isolated severe obesity. Unfortunately, parental
DNA samples were not available. This variant does not affect
the transcript encoding Gsα. The patient did not present with
any skeletal, endocrine or developmental defect. The clinical
significance of this missense variant thus remains uncertain.
We furthermore identified four heterozygous non-synonymous
amino acid changes in GNAS exon XL and one change in exon
NESP, as well as single variants in PRKAR1A and in PDE4D.
All these amino acid changes were present in gnomAD with
comparable or higher allele frequencies and were not predicted
to be disease-causing variants.
We did not identify any pathogenic defects in the investigated
genes. Although we had carefully selected our patients presenting
severe obesity with early onset, the relatively small cohort size of
only 88 patients can be regarded as a limitation. Furthermore,
patients with PHP and related disorders may have been identified
earlier by pediatricians and could therefore not be included in
our study.
Another limitation of our study was the lack of a control
group of normal-weight subjects. However, we compared
the allele frequencies of the identified variants with the
Finnish population in gnomad and SISu project, which include
genotype data of more than 10,000 individuals from the
Finnish population.
In conclusion, our results suggest that mutations in GNAS,
PDE4D, and PRKAR1A, and methylation changes in GNAS
locus do not play a significant role in etiology of childhood-
onset obesity in our Finnish cohort of patients, who lacked
biochemical features of pseudohypoparathyroidism and
related disorders.
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